KPL-404
Rheumatoid Arthritis
Phase 2Active
Key Facts
About Kiniksa Pharmaceuticals
Kiniksa Pharmaceuticals is a publicly traded biopharma focused on immune modulation for cardiovascular and autoimmune diseases with high unmet need. Founded in 2015, its key achievement is the FDA approval and commercialization of ARCALYST® (rilonacept), the first and only therapy for recurrent pericarditis, providing a foundational revenue stream. The company's strategy leverages strategic in-licensing and targeted development of biologics with strong biologic rationale, building a balanced portfolio that spans commercial and clinical-stage assets. This approach, led by a seasoned team with a proven track record in rare diseases, aims to deliver differentiated therapies rapidly.
View full company profileTherapeutic Areas
Other Rheumatoid Arthritis Drugs
| Drug | Company | Phase |
|---|---|---|
| Early Detection Test for Rheumatoid Arthritis | Age Labs | Development |
| Piclidenoson (CF101) | Can Fite Biopharma | Phase II/III |
| ERNA-201 | Eterna Therapeutics | Preclinical |
| Tc99m Tilmanocept | Navidea Biopharmaceuticals | Phase 2/3 |
| Monoclonal Antibody Biosimilar (Anti‑TNF) | USV Biologics Division | Phase 1 |
| Targeted Immunotherapy for Rheumatoid Arthritis (via Arthritis4Cure) | LFB | Pre-clinical |
| EYD-001 (Takinib analog) | EydisBio | Preclinical |
| LFD-200 | Lifordi Immunotherapeutics | Phase 1 |
| MEV-N01 | Mesenbio | Pre-clinical |
| CIT-013 | Citryll | Phase 2a |
| Restem-L | Restem | Phase 2 |
| ASIT Platform | Ahead Therapeutics | Pre-clinical |